Related Experiment Video
Updated: Jun 23, 2026
Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
Published on: June 8, 2019
Prognostic significance of circulating tumor DNA as a baseline or dynamic factor in advanced NSCLC without oncogenic
M E Andersen1, E M Hedegaard2, S W C Wen3
1Department of Clinical Oncology and Palliative Care, Zealand University Hospital, Vestermarksvej 9, 2, Roskilde 4000, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, Copenhagen N 2200, Denmark.
Abstract:
Prognostic biomarkers for advanced non-oncogene-addicted non-small cell lung cancer (NSCLC) remain limited. This PRISMA-compliant systematic review assessed the prognostic value of plasma circulating tumor DNA (ctDNA) at baseline and its dynamics during treatment. Cochrane, EMBASE, and MEDLINE were searched to February 27, 2025, identifying studies reporting hazard ratios (HRs) for overall survival (OS). Bias was evaluated using the Quality in Prognostic Studies tool, and publication bias with funnel plots and Egger's regression. Among 7118 records, 43 studies were included, spanning diverse designs, ctDNA assays, quantification units, and definitions of dynamic change. Detectable or elevated baseline ctDNA was associated with worse OS (HR 1.62; 95 % CI 1.40-1.87) with substantial heterogeneity and possible small-study bias. Increasing or persistent ctDNA during treatment was strongly prognostic for poor survival (HR 2.69; 95 % CI 2.35-3.09). Overall study quality was moderate to high. Plasma ctDNA shows consistent prognostic value, though clinical implementation is limited by methodological variability.
More Related Videos
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Related Concept Videos
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...